Literature DB >> 8765624

A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin.

M P Meyer1, C Haworth, J H Meyer, A Commerford.   

Abstract

OBJECTIVE: To determine whether intravenously administered iron supplements would improve the hematologic response to recombinant erythropoietin in stable preterm infants.
METHODS: Forty-two preterm infants (<33 weeks' gestation, birth weight < 1500 gm, hematocrit <38%) were treated with recombinant human erythropoietin (Eprex), 600 U/kg per week, and randomly assigned to receive either an oral preparation of ferrous lactate (elemental iron, 12 mg/kg per day) or an intravenous preparation of iron sucrose (6 mg/kg per week).
RESULTS: Hematocrits, reticulocyte counts, and transfusions were similar in the oral group (OG) and the intravenous group (IVG). However, markedly higher serum ferritin concentrations were noted in the IVG (p <0.001), and by completion of the study the arithmetic mean values were 265 +/- 127 microg/L versus 137 +/- 65 microg/L in the IVG and the OG, respectively. The numbers of hypochromic erythrocytes increased in both groups during the study but were significantly higher in the OG (p = 0.04). Mean daily weight gain in the IVG (27 +/- 6.4 gm/day) was greater than in the OG (22.9 +/- 4.78 gm/day; p = 0.04).
CONCLUSIONS: High doses of both orally administered iron and intravenously administered iron sucrose appear to supply sufficient iron for erythropoiesis in stable infants. Storage iron may become depleted after oral supplementation. The intravenous preparation appears to be safe and maintains serum ferritin concentrations, and it may be indicated for patients with low ferritin levels and for those not established on enteral feedings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765624     DOI: 10.1016/s0022-3476(96)70251-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

Review 1.  Reticulocytes and reticulocyte enumeration.

Authors:  R S Riley; J M Ben-Ezra; R Goel; A Tidwell
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 2.  Is supplementary iron useful when preterm infants are treated with erythropoietin?

Authors:  F C Ridley; J Harris; R Gottstein; A J B Emmerson
Journal:  Arch Dis Child       Date:  2006-12       Impact factor: 3.791

3.  Intravenous iron administration together with parenteral nutrition to very preterm Jehovah's Witness twins.

Authors:  Porntiva Poorisrisak; Allan Mikael Schroeder; Gorm Greisen; Gitte Zachariassen
Journal:  BMJ Case Rep       Date:  2014-06-02

Review 4.  Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity.

Authors:  Robin K Ohls
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  End-stage kidney disease in infancy: an educational review.

Authors:  Keia R Sanderson; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2018-11-21       Impact factor: 3.714

Review 6.  Anaemia of prematurity. Epidemiology, management and costs.

Authors:  M P Meyer
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

7.  Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants.

Authors:  V P Carnielli; R Da Riol; G Montini
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-07       Impact factor: 5.747

8.  Reticulocyte enrichment of zinc protoporphyrin/heme discriminates impaired iron supply during early development.

Authors:  Sharon E Blohowiak; Melinda E Chen; Kristin S Repyak; Nicole L Baumann-Blackmore; David P Carlton; Michael K Georgieff; Thomas D Crenshaw; Pamela J Kling
Journal:  Pediatr Res       Date:  2008-07       Impact factor: 3.756

9.  Effects of vitamin E supplementation during erythropoietin treatment of the anaemia of prematurity.

Authors:  A Pathak; P Roth; J Piscitelli; L Johnson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-07       Impact factor: 5.747

10.  Red blood cell transfusions in newborn infants: Revised guidelines.

Authors: 
Journal:  Paediatr Child Health       Date:  2002-10       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.